Publications by authors named "Leorah Ross"

Claim this Profile
O
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
Ania M Jastreboff, Donna H Ryan, Harold E Bays, Peter R Ebeling, Mia G Mackowski, Leorah Ross

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Franco Locatelli, Peter Lang, Donna Wall, Roland Meisel, Selim Corbacioglu, Leorah Ross

N Engl J Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Identical INN "Imiglucerase" for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database.
So-Fai Tsang, Shirali Pandya, Kristina Barakov, Joan Keutzer, Grace Lewis, Leorah Ross

Drug Saf· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations.
Jeremy N Ruskin, Catherine Ortemann-Renon, Jerome Msihid, Leorah Ross, Ana Cristina Puga

Mol Genet Metab· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents.
Nathan Thibault, Jennifer Ibrahim, M Judith Peterschmitt, Ana Cristina Puga, Leorah Ross

Mol Genet Metab· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1.
Lucie Vu, Gerald F Cox, Jennifer Ibrahim, M Judith Peterschmitt, Leorah Ross

Mol Genet Metab Rep· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
Timothy M Cox, Guillermo Drelichman, Renata Cravo, Manisha Balwani, Thomas Andrew Burrow, Leorah Ross

Lancet· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
Pramod K Mistry, Elena Lukina, Hadhami Ben Turkia, Dominick Amato, Hagit Baris, Leorah Ross

JAMA· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Elena Lukina, Nora Watman, Marta Dragosky, Gregory M Pastores, Elsa Avila Arreguin, Leorah Ross

Blood Cells Mol Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
Annette T Byrne, Leorah Ross, Joceyln Holash, Mikiye Nakanishi, Limin Hu

Clin Cancer Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis